Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
14041
Supplementary file 1_Comparative effects of high-intensity interval training versus moderate-intensity continuous training on body composition and blood pressure in overweight adol...
Published 2025“…</p>Conclusion<p>Both HIIT and MICT demonstrated comparable effects on most outcomes in overweight/obese adolescents. HIIT showed a modest, borderline significant advantage in reducing body fat percentage, while MICT appeared more effective in reducing waist circumference in the running subgroup. …”
-
14042
Table1_Assessing physical fitness adaptations in collegiate male soccer players through training load parameters: a two-arm randomized study on combined small-sided games and runni...
Published 2024“…Although there were positive trends in variables such as RSA and 30-15IFT, these changes were modest and not statistically significant. The results suggest that while the combined SSGs and HIIT approach shows potential, its impact on physical fitness over a 4-week period is limited, with some variables, like CMJ, even showing decreases.…”
-
14043
<i>Stenotrophomonas</i> sp. SI-NJAU‑1 and Its Mutant Strain with Excretion-Ammonium Capability Promote Plant Growth through Biological Nitrogen Fixation
Published 2025“…Additionally, SI-NJAU-1 was proven to decrease the application of compound fertilizers by 30%. …”
-
14044
Data Sheet 1_Global, regional, and national burden and trends of intracerebral hemorrhage among adolescents and young adults aged 15–39 years from 1990 to 2021: a comprehensive tre...
Published 2025“…Background<p>Intracerebral hemorrhage (ICH) poses a significant health challenge, notably affecting adolescents and young adults (AYAs) aged 15–39 years. …”
-
14045
<b>Increasing ECM tree dominance enhances </b><b>soil </b><b>lignin </b><b>phenols </b><b>but suppresses microbial necromass contribution to soil organic carbon in a subtropical </...
Published 2025“…Our results indicated that ECM% did not affect SOC content but significantly altered SOC composition. Specifically, a higher ECM% promoted accumulation of plant-derived C and reduced microbial-derived C. …”
-
14046
Analyses of directed phase lag index (dPLI [44]) for excitatory/inhibitory (E/I) ratios with respect to pyramidal (Pyr) and parvalbumin (PV) populations (<i>A</i>) and Pyr and soma...
Published 2025“…However, in contrast to the E/I ratio for the PV population, increasing the E/I ratio by decreasing SOM interneuron numbers tended to decrease the dPLI values from PV to Pyr populations. …”
-
14047
-
14048
-
14049
Data Sheet 1_A novel short-course, low-intensity blood-flow-restricted exercise (BFRE) regimen to study satellite cell function in critical illness survivors with sustained muscle...
Published 2025“…In controls, satellite cell content and MuRF1 transcript expression were significantly higher (1.53 ± 0.30- and 1.34 ± 0.31-fold difference, respectively) and myostatin transcript expression was significantly lower (0.58 ± 0.31-fold difference) in BFRE-trained versus untrained VL. …”
-
14050
<b>Efficacy of </b><b>GLP-1-based Therapies on</b><b> </b><b>Metabolic Dysfunction-Associated Steatotic</b><b> Liver Disease and </b><b>Metabolic Dysfunction-Associated</b><b> Stea...
Published 2025“…Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with the retatrutide displaying the most obvious treatment effects. …”
-
14051
Protein levels of Bcl-2 family markers in limbal stromal cells (LSCs) and in Aniridia-LSCs (AN-LSCs), after treatment with 0 µM, 50 µM and 75 µM Cobalt chloride (CoCl<sub>2</sub>),...
Published 2025“…In addition, 75 µM CoCl₂ treatment significantly decreased Bcl-2 protein level both in LSCs and AN-LSCs (p = 0.0484; p = 0.0405).…”
-
14052
Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14053
Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14054
Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14055
Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14056
Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14057
Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14058
Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14059
Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14060
Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”